Description of the medicine: Hydroxyurea (Hydroxyurea)
Urea hydroxy derivative (see).
Synonyms: Hydrea, Hydroxycarbamide, Hydrea, Biosupressin, Hidrix, Hydroxycarbamide, Hydroxycarbamidum, Hydura, Litaliz, Onco-carbamidi.
As a chemical compound, hydroxyurea was synthesized in 1869, and only in 1982 the clinical effectiveness of its use in the treatment of certain forms of cancer was proved.
Hydroxyurea is used to treat chronic myelogenous leukemia, lymphogranulomatosis, melanoma, and breast cancer metastases.
The antitumor mechanism is associated with the ability of the compound to inhibit ribonucleoside diphosphate reductase, which is one of the key enzymes involved in DNA biosynthesis.
The drug is easily absorbed when taken orally, the peak in plasma concentration is observed after 1 - 2 hours, the half-life is about 2 hours. It passes through the blood-brain barrier. About 80% is excreted in the urine within 12 hours.
Take orally in capsules containing 0.5 g of hydroxyurea. Usually, 1 capsule is prescribed 3-4 times a day. The course of treatment is 3 to 4 weeks. There are also other treatment regimens (80 mg / kg once every 3 days; 20 - 30 mg / kg daily; duration of treatment is 6 weeks).
The drug is usually well tolerated. Perhaps the development of dyspeptic phenomena, skin allergic reactions, rarely stomatitis, as well as leukopenia, megaloplastic anemia, thrombocytopenia.
Side effects usually pass quickly after discontinuation of the drug.
Hydroxyurea is contraindicated in severe violations of bone marrow function, severe anemia and severe leukopenia, while breastfeeding,
Release form: in capsules of 0.5 g in a package of 100 pieces.